Local tumor control in patients with neuroendocrine neoplasms treated with stereotactic ablative radiotherapy (SBRT)

#3739

Introduction: Neuroendocrine neoplasms (NEN) represent a diverse group of malignancies. Anatomic origin, histology and biological behaviour vary extensively. The treatment armamentarium includes surgery (first choice when possible), systemic therapy and localised treatment modalities. The role of radiotherapy is not yet established, but studies indicate that local tumor control (LTC) can be achieved by high-dose radiotherapy. Stereotactic ablative radiotherapy (SBRT) is high doses of radiation delivered to a small target, with potential of achieving local tumor control.

Aim(s): To investigate the one-year LTC-rate in patients with NEN treated with SBRT.

Materials and methods: Patients with NEN of different origin and grade, treated with SBRT from 2003-2021 were retrospectively identified. Patient characteristics and details of the SBRT were collected. Response to treatment and local/distant progression was determined based on existing imaging reports. One-year LTC-rate and systemic control (SC)-rate, local response duration, progression free survival (PFS) and overall survival (OS) were described.

Conference:

Presenting Author:

Authors: Nygaard Dowler A, Aggerholm Pedersen N, Knap Marquard M, Dam G, Tabaksblat E,

Keywords: neuroendocrine, stereotactic radiotherapy, sbrt, local control,